Skip to content
← Full study record

NCT00514137 · OUTCOME

Duration of Response

Sunitinib in Treating Patients With Relapsed Multiple Myeloma · Source last updated 2014-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From the documentation of response until the date of progression

What was measured

The distribution of duration of response will be estimated using the method of Kaplan-Meier.

Analysis population: No analysis was done because there were no confirmed responses.

Groups in this outcome

Treatment (Kinase Inhibitor Therapy)

Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Kinase Inhibitor Therapy)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
The distribution of duration of response will be estimated using the method of Kaplan-Meier.
groups
  1. description
    Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Kinase Inhibitor Therapy)
population Description
No analysis was done because there were no confirmed responses.
reporting Status
POSTED
time Frame
From the documentation of response until the date of progression
title
Duration of Response
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice